The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and to explore the biomarkers related to efficacy and adverse event.
Postoperative patients with pathological confirmed locally advanced gastric cancer, hepatocellular carcinoma, non-small cell lung cancer and colorectal cancer with standard adjuvant treatment are enrolled. This is a prospective exploratory trial. Patients' tumor tissues are subsequent to whole exosome sequencing and possible neoantigens are identified. DC is in vitro primed with synthesized peptides. Both adverse events and responses are recorded.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
80
subcutaneous administration
Qiu Li
Chengdu, Sichuan, China
RECRUITINGDisease-free Survival (DFS)
Defined as the time from the surgery to the first documented disease recurrence or death (by any cause), whichever occurs first
Time frame: Up to 5 years
Overall Survival (OS)
Defined by the time between the date of randomization and the date of death
Time frame: Up to 10 years
Incidence of Treatment-Related Adverse Events [Safety and Tolerability]
Defined by treatment-related adverse events as assessed by CTCAE v4.0
Time frame: 3 months after the last administration of cells
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.